Every 10-Q that COMPASS Pathways Plc (CMPS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CMPS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CMPS filings page.
Compass Pathways plc reported a net loss of $162.6 million for the six months ended June 30, 2026, compared with $56.3 million a year earlier. Results were heavily affected by a $74.7 million year‑to‑date non‑cash loss from fair value changes in warrant liabilities and higher general and administrative spending tied to commercial preparation.
Operating expenses for the six months were $95.3 million, including research and development of $55.7 million and general and administrative of $39.6 million. Cash and cash equivalents grew to $433.3 million from $149.6 million at year‑end, driven by equity offerings, warrant exercises and additional Hercules term debt; the company states this should fund operating and capital needs into 2028.
Total assets were $504.6 million, liabilities $420.0 million and shareholders’ equity improved from a deficit to $84.5 million, despite sizable warrant liabilities of $337.5 million. Clinically, both pivotal Phase 3 TRD trials (COMP005 and COMP006) met primary endpoints with statistically significant, clinically meaningful MADRS reductions, supporting an ongoing rolling NDA review with the FDA and a National Priority Voucher, while a Phase 2b/3 PTSD trial (COMP202) is initiating under an accepted IND.
Compass Pathways plc reports strong Q1 2026 results, with net income of $91.2 million, driven primarily by a $130.9 million non-cash gain from the fair value change of warrant liabilities. Core operations still produced a loss from operations of $42.9 million as the company continues investing in late-stage development.
Cash and cash equivalents rose to $466.0 million, supported by warrant exercises, a February 2026 underwritten ADS offering, and a new Hercules loan tranche, lifting total assets to $531.7 million. Management believes this cash should fund operating expenses and capital needs into 2028.
Clinically, Compass advanced its COMP360 psilocybin program in treatment-resistant depression, with both pivotal Phase 3 trials (COMP005 and COMP006) meeting primary endpoints and the FDA granting rolling review and a Commissioner’s National Priority Voucher. The company is also initiating a Phase 2b/3 COMP360 trial in PTSD while maintaining a substantial accumulated deficit of $731.4 million.
COMPASS Pathways filed its Q3 2025 10‑Q, reporting a net loss of $137.7 million for the quarter. The loss was primarily driven by a $101.3 million fair value change of warrant liabilities, a non‑cash item tied to January 2025 financing warrants.
Operating expenses were $40.5 million, including $27.3 million in research and development and $13.2 million in general and administrative. Cash and cash equivalents were $185.9 million as of September 30, 2025. Shareholders’ equity was $37.6 million, reflecting $165.6 million of warrant liabilities on the balance sheet.
The company reported that its first Phase 3 TRD trial (COMP005) met its primary endpoint, and it plans to submit a proposal for rolling NDA submission to the FDA. It expects to disclose additional Phase 3 efficacy and safety data in 2026. The company states its cash is sufficient to fund operations into 2027. Ordinary shares outstanding were 96,017,044 as of October 30, 2025.